NCT05812014 - Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older | Biotech Hunter

Enrollment

9,800

Participants

Timeline

Start Date

March 25, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

June 30, 2024

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL

SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)

One dose was administered by intramuscular injection, 100μg，1.0ml/dose

DRUG

0.9% sodium chloride solution

One dose was administered by intramuscular injection, 1.0ml/dose

Trial Locations (1)

RECRUITING

Sindh Infectious Diseases Hospital & Research Center Dow University of Health Sciences, Islamabad